ORPHA:2092
Focal dermal hypoplasia
Also known as: Goltz syndrome · Goltz-Gorlin syndrome
Publications
3,309
Trials
0
Interventional, condition-specific
Researchers
1,005
Distinct authors in sample
Gene link
PORCN
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare multiple anomalies/ syndrome characterized by abnormalities in ectodermal- and mesodermal-derived tissues, classically manifesting with skin abnormalities, limb defects, ocular malformations, and mild facial dysmorphism.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010592
- MeSH:D005489
- OMIM:305600
- UMLS:C0016395
- NCIT:C84715
Additional Mondo synonyms (2)
focal dermal hypoplasia · focal dermal hypoplasia, X-linked dominant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.
- Gene identifiedPresent
Definitive — PORCN
- LiteraturePresent
3,309 matched papers (2,050 in last 10 years) Source
- Phenotype characterisedPresent
156 HPO annotations (e.g. Multicystic kidney dysplasia; Umbilical hernia; Diastasis recti) Source
- Animal modelPresent
14 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PORCN).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
156
Associated phenotypes · MONDO:0010592
- Multicystic kidney dysplasia
- Umbilical hernia
- Diastasis recti
- Dermal atrophy
- Abnormal epiphysis morphology
Showing 5 of 156 — open Monarch for the full list.
Animal models (Monarch / Alliance)
14
Model associations linked to this Mondo ID
- Porcntm1Vdv/Y [background:] chimera involves: 129S5/SvEvBrd * C57BL/6J·MGI:5435560·Mus musculus
- Porcntm1.1Vdv/Y Tg(EIIa-cre)C5379Lmgd/0 [background:] involves: 129S4/SvJaeSor * 129S5/SvEvBrd * C57BL/6J * FVB/N·MGI:5435562·Mus musculus
- Porcntm1.1Vdv/Porcn+ Hprt1tm1(CAG-cre)Mnn/Hprt1+ [background:] involves: 129S/Sv * C57BL/6J·MGI:5435565·Mus musculus
- Porcntm1.1Vdv/Y Tg(Prrx1-cre)1Cjt/0 [background:] involves: 129S4/SvJaeSor * 129S5/SvEvBrd * C57BL/6 * SJL/J·MGI:5435567·Mus musculus
- Porcntm1Vdv/Porcn+ [background:] chimera involves: 129S5/SvEvBrd * C57BL/6J·MGI:5435559·Mus musculus
- Porcntm1.1Vdv/Porcn+ Tg(EIIa-cre)C5379Lmgd/0 [background:] involves: 129S4/SvJaeSor * 129S5/SvEvBrd * C57BL/6J * FVB/N·MGI:5435561·Mus musculus
- Porcntm1.1Vdv/Y Tg(KRT14-cre)1Efu/0 [background:] involves: 129S4/SvJaeSor * 129S5/SvEvBrd * C57BL/6J·MGI:5435568·Mus musculus
- Porcntm1.1Lcm/Porcn+ Edil3Tg(Sox2-cre)1Amc/Edil3+ [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA·MGI:5049887·Mus musculus
- Porcntm1.1Lcm/Porcntm1.2Lcm [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1·MGI:6368182·Mus musculus
- Porcntm1.1Lcm/Y Tg(rx3-icre)1Mjam/0 [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1·MGI:6368183·Mus musculus
- Porcntm1.1Lcm/Y H2az2Tg(Wnt1-cre)11Rth/H2az2+ Tg(rx3-icre)1Mjam/0 [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J * CD-1·MGI:6368186·Mus musculus
- Porcntm1.2Lcm/Porcntm1.2Lcm [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * DBA/2·MGI:6368188·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,309
3,309 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,309 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,050 in the last 10 years · low confidence
Phrase hits: 1,819 · MeSH hits: 0
Who's working on it?
1,005
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Dika E3 papers · 2024
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Papers in Europe PMC - 02Dutta A3 papers · 2024
Department of Pediatrics, North Bengal Medical College, West Bengal, India.
Papers in Europe PMC - 03Fete M3 papers · 2024
National Foundation for Ectodermal Dysplasias, Fairview Heights, Illinois.
Papers in Europe PMC - 04Grzeschik KH3 papers · 2024
Institut für Allgemeine Humangenetik, Philipps-Universitaet, Marburg, Germany.
Papers in Europe PMC - 05Lambertini M3 papers · 2024
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Papers in Europe PMC - 06Lombardi MP3 papers · 2017
Department of Clinical Genetics, Academisch Medisch Centrum, Amsterdam, The Netherlands.
Papers in Europe PMC - 07Abbott BM2 papers · 2024
National Foundation for Ectodermal Dysplasias, Fairview Heights, Illinois, USA.
Papers in Europe PMC - 08Abdelhammed MH2 papers · 2025
Pathology & Immunology, Baylor College of Medicine, Houston, TX.
Papers in Europe PMC - 09Abdulwahab AH2 papers · 2023
Department of Radiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Papers in Europe PMC - 10Ai Y2 papers · 2026
Department of Dermatologic Surgery, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi 330001, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 2 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- ctis·2023-507528-21-00·Authorised, recruiting·A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Focal dermal hypoplasia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Focal dermal hypoplasia" OR "Goltz syndrome" OR "Goltz-Gorlin syndrome" OR "focal dermal hypoplasia, X-linked dominant") OR ("PORCN" OR "PORCN syndrome" OR "PORCN-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Focal dermal hypoplasia" OR "Goltz syndrome" OR "Goltz-Gorlin syndrome" OR "focal dermal hypoplasia, X-linked dominant"
Study-type breakdown: 0 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (3309) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T19:05:48.789Z
